New Parkinson's injection enters human safety testing
NCT ID NCT06659562
Summary
This early-stage study tested the safety and how the body processes a new drug called HER-096, given as an injection under the skin. It involved two groups: healthy volunteers who received a single dose, and patients with early Parkinson's disease who received multiple doses over four weeks. The main goal was to see if the drug was safe and well-tolerated, while also checking for any changes in Parkinson's symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE, IDIOPATHIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Services Turku - CRST Oy
Turku, Finland, Finland
Conditions
Explore the condition pages connected to this study.